Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Conditions: B-cell Non-Hodgkin Lymphoma Interventions: Drug: Rocbrutinib; Biological: Rituximab; Drug: Cyclophosphamide; Drug: doxorubicin; Drug: Vincristin; Drug: Prednisone Sponsors: Guangzhou Lupeng Pharmaceutical Company LTD. Not yet recruiting

https://clinicaltrials.gov/study/NCT06251180

Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials